CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $25.05M, above the global median of $18.73M
- FinancialsAltman Z-Score 1.68: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.83BCNY423.09M · vs all stocks (USD)
Revenue (TTM)
990.47MCNY147.91M · vs all stocks (USD)
Profit Margin
-17.22%vs Biotechnology peers
Beta
0.8530xvs all stocks
52-Week Change
31.80%vs all stocks
Market Capitalization
2.83BCNY423.09M · vs all stocks (USD)
Enterprise Value
3.39BCNY505.96M · vs all stocks (USD)
Price to Sales (TTM)
2.86xvs Biotechnology peers
Price to Book (MRQ)
1.69xvs Biotechnology peers
Enterprise to Revenue
3.42xvs Biotechnology peers
Gross Margin
27.24%vs Biotechnology peers
Profit Margin
-17.22%vs Biotechnology peers
Operating Margin
-49.11%vs Biotechnology peers
Return on Assets (TTM)
-3.20%vs Biotechnology peers
Return on Equity (TTM)
-9.59%vs Biotechnology peers
Revenue (TTM)
990.47MCNY147.91M · vs all stocks (USD)
Revenue per Share (TTM)
8.71CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-10.40%vs Biotechnology peers
Gross Profit (TTM)
122.22MCNY18.25M · vs all stocks (USD)
EBITDA (TTM)
128.45MCNY19.18M · vs all stocks (USD)
Net Income (TTM)
-170.54MCNY-25.47M · vs all stocks (USD)
Operating Cash Flow (TTM)
20.30MCNY3.03M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
167.73MCNY25.05M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
940.19MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
718.12MCNYFY2025 · Dec 31, 2025Gross Profit
222.07MCNYFY2025 · Dec 31, 2025Operating Income
-30.53MCNY-4.56M · vs all stocks (USD)
Pre-tax Income
-88.57MCNYFY2025 · Dec 31, 2025Income Tax Expense
-6.14MCNYFY2025 · Dec 31, 2025Net Income
-82.43MCNYFY2025 · Dec 31, 2025EBIT
-71.23MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
128.45MCNYFY2025 · Dec 31, 2025Research & Development
86.76MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
63.44MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.64MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.67MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
17.35MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.7200CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.7200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
114.43MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
114.43MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-82.43MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
40.16KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-120.57MCNYFY2025 · Dec 31, 2025Free Cash Flow
-193.39MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
243.97MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-82.43MCNYFY2025 · Dec 31, 2025Other Non-cash Items
21.13MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-174.46MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
115.19MCNYFY2025 · Dec 31, 2025Capital Expenditures
-72.82MCNYFY2025 · Dec 31, 2025Purchase of Investments
-927.90MCNYFY2025 · Dec 31, 2025Sale of Investments
864.40MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-136.31MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
358.98MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-155.78MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.61MCNYFY2025 · Dec 31, 2025Other Financing Charges
-34.90MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
159.68MCNYFY2025 · Dec 31, 2025Shares Outstanding
114.72MSharesUpdated Sep 22, 2026% Held by Insiders
56.96%vs all stocks
% Held by Institutions
0.54%vs all stocks
Total Cash (MRQ)
399.71MCNY59.69M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.44CNYUpdated Sep 22, 2026Total Debt (MRQ)
916.35MCNY136.84M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5379xvs Biotechnology peers
Current Ratio (MRQ)
1.97xvs Biotechnology peers
Book Value per Share (MRQ)
14.65CNYUpdated Sep 22, 2026Total Assets
3.34BCNY498.45M · vs all stocks (USD)
Total Current Assets
1.19BCNYFY2025 · Dec 31, 2025Total Liabilities
1.53BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.14BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
841.11MCNYFY2025 · Dec 31, 2025Total Current Liabilities
690.89MCNYFY2025 · Dec 31, 2025Cash
243.97MCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
243.97MCNYFY2025 · Dec 31, 2025Other Short-term Investments
120.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
147.25MCNYFY2025 · Dec 31, 2025Inventory
537.18MCNYFY2025 · Dec 31, 2025Accounts Payable
369.77MCNYFY2025 · Dec 31, 2025Short-term Debt
235.30MCNYFY2025 · Dec 31, 2025Other Current Liabilities
551.26KCNYFY2025 · Dec 31, 2025Long-term Debt
758.91MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
326.34KCNYFY2025 · Dec 31, 2025Common Stock (Book)
114.73MCNYFY2025 · Dec 31, 2025Retained Earnings
420.47MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.81BCNY269.68M · vs all stocks (USD)
Treasury Stock
20.29MCNYFY2025 · Dec 31, 202552-Week Low
13.71CNYUpdated Sep 22, 202652-Week High
26.58CNYUpdated Sep 22, 202652-Week Change
31.80%vs all stocks
Beta
0.8530xvs all stocks
50-Day MA
19.09CNYUpdated Sep 22, 2026200-Day MA
20.16CNYUpdated Sep 22, 2026Avg 10-Day Volume
11.88MSharesUpdated Sep 22, 2026Avg 30-Day Volume
7.87MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-1.49CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.68: grey zoneSignificant
Altman Z-Score: 1.68
Low earnings qualitySignificant
Earnings Quality Score: -1.03
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $25.05M, above the global median of $18.73MNotable
Levered free cash flow (USD): 25,046,480.573Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hua Medicine Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Canopy Growth Corporation
Tier 1ProductionApproval-Gated PipelineFlowRule
Orum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule